Douglas Pharmaceuticals Europe Limited Sustainability Profile
Douglas Pharmaceuticals Europe Limited, a prominent player in the pharmaceutical industry, is headquartered in New Zealand (NZ) and operates extensively across Europe. Founded in 1990, the company has established itself as a leader in the development and manufacturing of high-quality generic and branded pharmaceuticals. With a focus on prescription medications, Douglas Pharmaceuticals is renowned for its commitment to innovation and quality, offering a diverse range of products that cater to various therapeutic areas. The company’s unique approach to formulation and production has positioned it favourably within the competitive landscape. Notable achievements include a robust portfolio of products that meet stringent regulatory standards, ensuring safety and efficacy for patients. Douglas Pharmaceuticals continues to expand its market presence, driven by a dedication to improving health outcomes across Europe and beyond.
DitchCarbon Score
How does Douglas Pharmaceuticals Europe Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Retail Trade Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Douglas Pharmaceuticals Europe Limited's score of 26 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Douglas Pharmaceuticals Europe Limited's reported carbon emissions
Douglas Pharmaceuticals Europe Limited, headquartered in New Zealand, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Additionally, there are no documented reduction targets or climate pledges associated with the company. As a result, Douglas Pharmaceuticals Europe Limited appears to be in the early stages of establishing its climate commitments and emissions reporting. Without specific emissions data or reduction initiatives, it is unclear how the company plans to address its carbon footprint or align with industry standards for sustainability. In the context of the pharmaceutical industry, companies are increasingly expected to set science-based targets and engage in transparent reporting of their emissions. As Douglas Pharmaceuticals Europe Limited develops its climate strategy, it may consider adopting such practices to enhance its environmental responsibility and align with global climate goals.
How Carbon Intensive is Douglas Pharmaceuticals Europe Limited's Industry?
How Carbon Intensive is Douglas Pharmaceuticals Europe Limited's Location?
Douglas Pharmaceuticals Europe Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Douglas Pharmaceuticals Europe Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
